Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum.
Gescher
Andreas J
AJ
Cancer Biomarkers and Prevention Research Group, Department of Oncology, University of Leicester, Leicester LE2 7LX, United Kingdom. ag15@le.ac.uk
Steward
William P
WP
D020533:Angiogenesis Inhibitors; D000818:Animals; D016588:Anticarcinogenic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001682:Biological Availability; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control / Q000628:therapy; D010166:Palliative Care; D010636:Phenols; D000077185:Resveratrol; D012264:Ribonucleotide Reductases; D012377:Rodentia; D013267:Stilbenes / Q000493:pharmacokinetics* / Q000494:pharmacology*; D014665:Vasodilator Agents
D020533:Angiogenesis Inhibitors; D016588:Anticarcinogenic Agents; D010636:Phenols; D013267:Stilbenes; D014665:Vasodilator Agents; D012264:Ribonucleotide Reductases; D000077185:Resveratrol